Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Uveal Melanoma 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Phase IB 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesonephric Gynecologic Cancer 1Lymphoma 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Cancer 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

trifluridine tipiracil drug combination 1regorafenib 1defactinib 1Oxaliplatin 1HMPL-013 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Colorectal Cancer × defactinib × 1 year × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡